Out of stock
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Xelpac
Beacon Pharmaceuticals PLC
Generic: Paclitaxel
Safety Advices
বাংলা
English
UNSAFE
It is unsafe to consume alcohol with Xelpac.
CONSULT YOUR DOCTOR
Xelpac is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
UNSAFE
Xelpac is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
UNSAFE
Xelpac may cause side effects which could affect your ability to drive.
As there is no reason why you cannot continue driving between courses of Xelpac but you should remember that this medicine contains some alcohol and it may be unwise to drive
SAFE IF PRESCRIBED
Xelpac is safe to use in patients with kidney disease. No dose adjustment of Xelpac is recommended.
However, talk to your doctor if you have any underlying kidney disease.
CAUTION
Xelpac should be used with caution in patients with liver disease. Dose adjustment of Xelpac may be needed. Please consult your doctor.
Use of Xelpac is not recommended in patients with severe liver disease.
Medicine Overview of Xelpac 30mg/vial Injection
Introduction
Xelpac is an anti-cancer medication used for the treatment of breast cancer, pancreatic cancer and non-small cell lung cancer. It is given as an injection by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for and may change from time to time. You should take it exactly as your doctor has advised. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see...
... Show moreUses of Xelpac
- Breast cancer
- Non-small cell lung cancer
- Pancreatic cancer
Side effects of Xelpac
Common
- Nausea
- Vomiting
- Weakness
- Low blood platelets
- Rash
- Upper respiratory tract infection
- Urinary tract infection
- Bleeding
- Anemia (low number of red blood cells)
- Flushing (sense of warmth in the face, ears, neck and trunk)
- Hair loss
- Decreased blood pressure
- Peripheral neuropathy (tingling and numbness of feet and hand)
- Diarrhea
- Decreased white blood cell count (neutrophils)
How to use Xelpac
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Xelpac works
Xelpac is an anticancer medication. It works by interfering with the microtubule structures which help the cancer cells to divide and multiply. This slows the growth of cancer cells and eventually kills them.
Quick Tips
- Xelpac is an anti-cancer medication used for the treatment of breast cancer, pancreatic cancer, and non-small cell lung cancer.
- It is given as an intravenous (IV) injection into your vein, usually over 1 hour and every three weeks.
- Do not take Xelpac if you are pregnant or breastfeeding. Use reliable methods of contraception to prevent pregnancy while taking this medicine.
- Your doctor may get regular blood tests done to monitor your blood cells and liver function during treatment with this medicine.
- Inform your doctor if you notice unexplained bruising or bleeding, sore throat, mouth ulcers, high temperature (fever) or other signs of infection.
- Talk to your doctor if you have sudden weight gain or if you have swelling in your arms and legs that doesn't go away.
Brief Description
Indication
Ovarian carcinoma, Breast cancer, Lung cancer, Kaposi's sarcoma
Administration
Reconstitution: Paclitaxel must be diluted before infusion. It can be diluted in 0.9% sodium chloride inj, 5% dextrose inj, 5% dextrose and 0.9% sodium chloride inj or 5% dextrose in lactated Ringer's inj to a concentration of 0.3-1.2 mg/ml.
Adult Dose
Intravenous Ovarian carcinoma Adult: Primary treatment (in combination with cisplatin or carboplatin): 135 mg/m2 infused over 24 hr followed by cisplatin and repeated at 3 wk intervals. Secondary treatment (as single agent): 135 or 175 mg/m2 infused over 3 hr once every 3 wk. Breast cancer Adult: Adjuvant therapy; 2nd line monotherapy or 1st line treatment with trastuzumab: 175 mg/m2 infused over 3 hr once every 3 wk for 4 courses; when used with trastuzumab, dose should be given the day after the 1st dose of trastuzumab or immediately after subsequent doses if well-tolerated. 1st line with doxorubicin: 220 mg/m2...
... Show moreChild Dose
Safety and efficacy not established
Contraindication
History of hypersensitivity (especially macrogol glycerol ricinolate). Patients with baseline neutropenia of <1500 cells/mm3 (<1000 cells/mm3 for kaposi's sarcoma). Pregnancy and lactation. In kaposi's sarcoma, contraindicated in patients with concurrent, serious, uncontrolled infections.
Mode of Action
Paclitaxel promotes microtubule formation by enhancing the action of tubulin dimers, stabilising existing microtubules and preventing their disassembly, thereby disrupting normal cell division in the late G2 mitotic phase of the cell cycle. This results in the inhibition of cell replication.
Precaution
Bone marrow suppression during therapy. Monitor cardiac function if conduction abnormalities result. Premedicaton (with corticosteroid, antihistamine and histamine H2-receptor antagonist) may be required to reduce risk of hypersensitivity reaction. Discontinue, if severe reactions e.g. hypotension, dyspnoea, angioedema or urticaria occur. Caution in patients with moderate hepatic impairment. Monitor for reactions of admin. Safety and efficacy in paediatric patients have not been established. Administer before platinum derivatives (cisplatin, carboplatin) if used in combination. Hazardous agent; use appropriate precautions for handling and disposal.
Lactation: not known if excreted in breast milk, do not nurse
Side Effect
>10%
Neutropenia (78-100%),Alopecia (55-96%),Anemia (47-96%),Arthralgia/myalgia (93%),Diarrhea (90%),Leukopenia (90%),Nausea/vomiting (9-88%),Opportunistic infections (76%),Peripheral neuropathy (42-79%),Thrombocytopenia (4-68%),Mucositis (5-45%),Hypersensitivity (2-45%),Renal impairment (34%),Hypotension (17%)
1-10%
Bradycardia (3%)
<1%
Grand mal seizures,Cardiac conduction abnormalities
Frequency Not Defined
Pyrexia,Dehydration,Pancytopenia,Congestive heart failure,Left ventricular dysfunction,Stevens-Johnson syndrome, toxic epidermal necrolysis, and extravasation
Potentially Fatal: Infections and infestations leading to death e.g. pneumonia and peritonitis.
Interaction
Myelosuppression was more profound when given after cisplatin than with the alternate sequence (e.g., paclitaxel before cisplatin). CYP2C8 inducers e.g. carbamazepine, phenobarbital, phenytoin, rifampicin, rifapentine, and secobarbital may reduce levels or effects. CYP2C8 inhibitors e.g. gemfibrozil, ketoconazole, montelukast, and ritonavir may increase levels or effects. CYP3A4 inducers e.g. aminoglutethimide, carbamazepine, nafcillin, nevirapine, phenobarbital, phenytoin, and rifamycins may decrease the levels or effects. CYP3A4 inhibitors e.g. azole antifungals, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, telithromycin, and verapamil may increase levels or effects. May increase anthracycline (eg doxorubicin, epirubicin) levels or toxicity; admin of anthracycline at...
... Show moreব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
